InnoCan Pharma Corporation
INNPD
$12.53
-$0.39-3.02%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.83M | 30.47M | 29.44M | 28.93M | 24.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.83M | 30.47M | 29.44M | 28.93M | 24.39M |
| Cost of Revenue | 3.33M | 3.16M | 3.25M | 2.86M | 2.44M |
| Gross Profit | 25.50M | 27.30M | 26.19M | 26.07M | 21.95M |
| SG&A Expenses | 24.12M | 25.54M | 25.89M | 25.56M | 22.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.51M | 30.01M | 30.68M | 30.15M | 27.17M |
| Operating Income | 318.00K | 454.00K | -1.25M | -1.22M | -2.78M |
| Income Before Tax | 629.00K | 2.17M | 919.00K | 334.00K | -2.20M |
| Income Tax Expenses | 937.00K | 1.21M | 1.18M | 1.34M | 926.00K |
| Earnings from Continuing Operations | -0.31 | 0.96 | -0.26 | -1.01 | -3.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.27M | -1.61M | -1.57M | -1.59M | -1.22M |
| Net Income | -1.58M | -649.00K | -1.83M | -2.60M | -4.34M |
| EBIT | 318.00K | 454.00K | -1.25M | -1.22M | -2.78M |
| EBITDA | 352.00K | 489.00K | -1.21M | -1.19M | -2.74M |
| EPS Basic | -0.35 | -0.15 | -0.44 | -0.63 | -1.07 |
| Normalized Basic EPS | -0.18 | -0.06 | -0.24 | -0.34 | -0.64 |
| EPS Diluted | -0.35 | -0.15 | -0.44 | -0.63 | -1.07 |
| Normalized Diluted EPS | -0.18 | -0.06 | -0.24 | -0.34 | -0.64 |
| Average Basic Shares Outstanding | 17.71M | 17.53M | 17.22M | 16.91M | 16.55M |
| Average Diluted Shares Outstanding | 17.71M | 17.53M | 17.22M | 16.91M | 16.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |